Effect of severe renal failure and haemodialysis on the pharmacokinetics of levosimendan and its metabolites
Abstract
The t(1/2) of the levosimendan metabolites was prolonged 1.5-fold and their AUC and C(max) were 2-fold in patients with severe CRF and ESRD patients undergoing haemodialysis as compared with healthy subjects. These results suggest that the dose should be reduced when levosimendan is used for the tre …
Keywords
National Center for Biotechnology Information
NCBI
NLM
MEDLINE
humans
pubmed abstract
nih
national institutes of health
national library of medicine
research support
non-u.s. gov't
algorithms
female
male
aged
middle aged
Clinical Trial
area under curve
half-life
phase i
heart rate / physiology
protein binding
blood pressure / physiology
kidney function tests
kidney failure
renal dialysis / adverse effects*
hydrazones / adverse effects
pyridazines / adverse effects
simendan
pmid:17328582
doi:10.2165/00003088-200746030-00004
jaakko puttonen
sampo kantele
pertti j pentikäinen
biotransformation
cardiotonic agents / adverse effects
cardiotonic agents / pharmacokinetics*
hydrazones / pharmacokinetics*
chronic / metabolism*
pyridazines / pharmacokinetics*
Access
Citation
ID:
269372
References
Blockchain Verification
Account:
NFT Contract Address:
0x95644003c57E6F55A65596E3D9Eac6813e3566dA
Article ID:
269372
Unique Identifier:
Network:
Scimatic Chain (ID: 481)
Loading...
Blockchain Readiness Checklist
Authors
Abstract
Journal Name
Year
Title
Creates 1,000,000 NFT tokens for this article
Token Features:
- ERC-1155 Standard NFT
- 1 Million Supply per Article
- Transferable via MetaMask
- Permanent Blockchain Record
Scan with Saymatik Web3.0 Wallet